Research graph
References from Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Local targets link to admitted publications; unresolved targets remain external evidence.
Back to the basics: the importance of concentration x time in oncology
10.1200/jco.1993.11.5.820 · 1993 · External reference
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
2000 · External reference
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
10.1172/jci8829 · 2000 · External reference
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
10.1172/jci9872 · 2000 · External reference
Metronomic chemotherapy: new rationale for new directions
10.1038/nrclinonc.2010.82 · 2010 · External reference
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives
10.1517/13543780903025752 · 2009 · External reference
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide
10.1007/bf00689054 · 1995 · External reference
Response of recurrent medulloblastoma to low-dose oral etoposide
10.1200/jco.1996.14.6.1922 · 1996 · External reference
Antiangiogenesis therapy. Current and future agents
10.1016/s0889-8588(05)70254-9 · 2001 · External reference
Looking at the seemingly contradictory role of vinblastine in anaplastic large-cell lymphoma from a metronomic perspective
10.1200/jco.2010.32.2883 · 2011 · External reference
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors
2002 · External reference
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer
10.1097/01.mph.0000183863.10792.d4 · 2005 · External reference
PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
10.1073/pnas.0711281105 · 2008 · External reference
Inhibition of tumor angiogenesis by oral etoposide
10.3892/etm.2010.127 · 2010 · External reference
Antiangiogenic metronomic chemotherapy for patients with recurrent embryonal and ependymal brain tumors
2010 · External reference
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study
2006 · External reference
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial
10.1002/pbc.21494 · 2008 · External reference
Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma
10.1002/cncr.10600 · 2002 · External reference
Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol
10.1002/cncr.20544 · 2004 · External reference
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas
10.1111/j.1651-2227.2010.01961.x · 2011 · External reference
A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors
10.1097/01.mph.0000243657.64056.c3 · 2006 · External reference
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours
10.1016/j.ejca.2006.03.023 · 2006 · External reference
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma
10.1016/j.ejca.2010.06.115 · 2010 · External reference
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study
10.1200/jco.2007.11.9230 · 2008 · External reference
10.1002/pbc.22821
10.1002/pbc.22821 · External reference
Children treated with metronomic chemotherapy in a low-income country:METRO-MALI-01
10.1097/mph.0b013e3182018ab8 · 2011 · External reference
Global child health priorities: what role for paediatric oncologists?
10.1016/j.ejca.2008.07.022 · 2008 · External reference
Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?
10.1097/mph.0b013e3182024918 · 2011 · External reference
Metronomic scheduling: the future of chemotherapy?
10.1016/s1470-2045(01)00587-3 · 2001 · External reference
Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
10.2217/fon.11.11 · 2011 · External reference
Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study
10.1016/s0149-2918(08)80059-8 · 2008 · External reference
Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children
10.1016/j.arcmed.2008.05.008 · 2008 · External reference
High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults
10.1002/pbc.20380 · 2005 · External reference
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens
10.1016/j.ejca.2009.01.002 · 2009 · External reference
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents
10.1158/0008-5472.can-09-0381 · 2009 · External reference
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
10.1016/j.ccr.2008.08.001 · 2008 · External reference
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
10.1126/science.1127592 · 2006 · External reference
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models
10.1158/1535-7163.mct-09-0583 · 2009 · External reference
Multiple circulating proangiogenic factors induced by sunitinib malate are tumorindependent and correlate with antitumor efficacy
10.1073/pnas.0708148104 · 2007 · External reference
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
10.1016/j.ccr.2009.01.021 · 2009 · External reference
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
10.1016/j.ccr.2009.01.027 · 2009 · External reference
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
10.1038/nrc1971 · 2006 · External reference
Endothelial progenitor cells: hope beyond controversy
10.2174/156800910793358041 · 2010 · External reference
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
10.1182/blood-2005-04-1422 · 2005 · External reference
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
2005 · External reference
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
10.1182/blood-2005-11-4570 · 2006 · External reference
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
10.1200/jco.2008.17.4789 · 2008 · External reference
Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab
10.1158/1078-0432.ccr-09-1493 · 2009 · External reference
Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
10.1126/science.1125950 · 2006 · External reference
Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy
10.1158/0008-5472.can-07-0905 · 2007 · External reference
Links between innate and cognate tumor immunity
10.1016/j.coi.2007.02.003 · 2007 · External reference
Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft
10.1111/j.1349-7006.2010.01807.x · 2011 · External reference
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
10.4161/cbt.8.16.9004 · 2009 · External reference
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide
10.1593/neo.101174 · 2011 · External reference
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1
10.1158/0008-5472.can-09-0167 · 2009 · External reference
Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy
10.1002/pbc.22382 · 2010 · External reference
